With the way the field is developing, new challenges have arisen in the research of treatments for thoracic malignancies. Speaking from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Keith Kerr, MBChB, FRCPath, FRCPE, of Aberdeen University Medical School, Aberdeen, UK, discusses these issues, ranging from clinical trials to biomarker testing.